Around the world, cases of human infection with swine-origin influenza viruses have been reported sporadically ([@R1]*--*[@R5]). From 1990 through 2010, a total of 27 cases of human infection with these viruses were confirmed by the US Centers for Disease Control and Prevention (CDC) ([@R4]*,*[@R6]). Of these cases, 21 were caused by triple-reassortant influenza A viruses (13 subtype H1N1, 1 subtype H1N2, and 7 subtype H3N2), which have inherited genes from classical swine, avian, and human influenza viruses. The 2009 influenza pandemic, caused by a variant triple reassortant influenza virus, influenza A(H1N1)pdm09 virus ([@R7]*,*[@R8]), proved that swine influenza viruses (SIVs) can cause widespread infection among humans and result in substantial economic costs. In 2010, an increase in the number of human cases of swine-origin influenza (H3N2) virus infection prompted selection of a candidate vaccine virus of swine origin, A/Minnesota/11/2010 (H3N2)v ([@R9]).

Systematic surveillance and characterization of novel viruses infecting humans and SIVs in swine are critical for early detection of viruses with pandemic potential. Since 2009, CDC has provided public health laboratories with a real-time reverse transcription PCR (rRT-PCR)--based assay for diagnostic testing for influenza ([@R10]). This assay enables detection and discrimination of influenza A virus subtypes H1N1, H3N2, and H1N1pdm09 and preliminary identification of triple-reassortant viruses possessing the nucleoprotein gene originating from SIVs.

The Study
=========

In 2011, public health laboratories in 5 states detected 12 cases of human infection with a novel variant of influenza virus, influenza A(H3N2)v virus, by using the CDC rRT-PCR protocol. Respiratory specimens from these patients were sent to CDC for virus confirmation. History of direct or indirect contact with swine was confirmed for 6 patients. However, swine contact could not be verified for the other 6, suggesting that these infections might have been contracted through limited person-to-person transmission ([@R11]*--*[@R13]) ([Table 1](#T1){ref-type="table"}). All 12 patients recovered fully from their illness ([@R10]*--*[@R12]).

###### Results of analysis of viral RNA isolated from original clinical samples from persons with influenza A(H3N2)v virus infection, United States, 2011\*

  Influenza virus strain    Contact with swine ([@R11]*--*[@R13])   Specimen collection date   Specimen type   rRT-PCR--positive results†   Genes sequenced‡
  ------------------------- --------------------------------------- -------------------------- --------------- ---------------------------- ----------------------------------------------
  A/Indiana/08/2011         No                                      Jul 24                     NPS             InfA, H3, pdmInfA            Full genome
  A/Pennsylvania/09/2011    Indirect                                Aug 20                     NPS             InfA, H3, pdmInfA            Full PB2, PB1, HA, NP, NA, M, NS, partial PA
  A/Pennsylvania/10/2011    Direct                                  Aug 26                     NPS             InfA                         Full NS, partial HA, M, NA
  A/Pennsylvania/11/2011    Indirect                                Aug 25                     NPS             InfA, H3, pdmInfA            Full PA, NP, NA, M NS, partial PB2, PB1, HA
  A/Maine/06/2011           Direct                                  Oct 10                     NPS             InfA, H3, pdmInfA            Full genome
  A/Indiana/10/2011§        Direct                                  Oct 22                     Cell culture    InfA, H3, pdmInfA            Full genome
  A/Maine/07/2011           Direct                                  Oct 24                     NPS             InfA                         Partial HA, M, NS
  A/Iowa/07/2011            No                                      Nov 14                     NPW             InfA, H3, pdmInfA            Full PB2, PB1, PA, NP, NA, M, NS, partial HA
  A/Iowa/08/2011            No                                      Nov 14                     NS              InfA, H3, pdmInfA            Full genome
  A/Iowa/09/2011            No                                      Nov 14                     NS              InfA, H3, pdmInfA            Full genome
  A/West Virginia/06/2011   No                                      Nov 21                     NW              InfA, H3, pdmInfA            Full genome
  A/West Virginia/07/2011   No                                      Dec 07                     NPS             InfA                         Partial HA, NA, M

\*Influenza A(H3N2)v, influenza virus variant identified in humans; rRT-PCR, real-time reverse transcription PCR; NPS, nasopharyngeal swab; PB, polymerase basic protein; HA, hemagglutinin; NP nucleoprotein; NA, neuraminidase; M, matrix protein; NS, nonstructural protein; PA, polymerase acidic protein; NPW, nasopharyngeal wash; NS, nasal swab. †Results obtained by using the Centers for Disease Control and Prevention Human Influenza Virus Real-Time RT-PCR Diagnostic Panel. ‡Sequences available from GenBank and the [Technical Appendix](#SD1){ref-type="local-data"} Table. §This patient was \>18 years of age; all others were \<18.

Genetic sequence analysis of RNA isolated from clinical respiratory specimens ([Table 1](#T1){ref-type="table"}) revealed that these influenza A(H3N2)v viruses possessed a combination of gene segments not previously found in humans ([Figure 1](#F1){ref-type="fig"}). Of the 8 gene segments, 7 (hemagglutinin, neuraminidase, polymerase basic proteins 1 and 2, polymerase acidic protein, nucleoprotein, and nonstructural protein) were similar to those of triple-reassortant SIV A(H3N2) currently circulating in North America and to those from human triple-reassortant influenza A(H3N2) viruses isolated in 2010 from Pennsylvania, Minnesota, and Wisconsin ([@R4]), including the proposed vaccine virus of swine origin, A/Minnesota/11/2010 ([@R14]) ([Figure 2](#F2){ref-type="fig"}, panel A; [Technical Appendix](#SD1){ref-type="local-data"} Figure). However, the M genes of all 2011 influenza A(H3N2)v viruses were inherited from a pandemic (H1N1) 2009 virus ([Figure 2](#F2){ref-type="fig"}, panel B). Although SIVs of subtypes A(H3N2) and A(H1N2) with the M gene of influenza A(H1N1)pdm09 virus have been detected in swine since 2009 ([@R15]), influenza A(H3N2)v virus possessing the M gene of influenza A(H1N1)pdm09 virus had not been detected in humans.
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According to genetic analysis results, amino acid diversity among influenza A(H3N2)v hemagglutinins was low (0--3 aa) compared with that of influenza A/Minnesota/11/2010. In addition, there have been no conserved amino acid changes in the hemagglutinin when comparing 2011 influenza A(H3N2)v from humans with 2011 influenza A(H3N2) SIVs. In particular, the known receptor binding site of the hemagglutinin protein of influenza A(H3N2)v virus was typical of SIV A(H3N2) viruses recently isolated in North America.

Hemagglutinins of the influenza A(H3N2)v viruses differed substantially from the hemagglutinin of the 2011--12 human seasonal vaccine virus, A/Perth/16/2011 (58--60 aa), which resulted from divergent evolutionary paths for the H3 hemagglutinin in swine and human viruses. The effect of these substitutions on virus antigenicity was examined in the hemagglutination-inhibition assay by using a panel of reference ferret antiserum. Hemagglutination-inhibition analysis of 6 available influenza A(H3N2)v virus isolates revealed no measureable inhibition by antiserum against the current human seasonal influenza A(H3N2) vaccine virus, A/Perth/16/2009 ([Table 2](#T2){ref-type="table"}), indicating that influenza A(H3N2)v virus is antigenically distinct from influenza A(H3N2) viruses currently circulating among humans.

###### Hemagglutinin-inhibition assay results, including the 6 available influenza A(H3N2)v viruses isolated in 2011, United States\*

  Influenza virus strain (culture method)   Titers to reference ferret antiserum   Specimen collection date                                                  
  ----------------------------------------- -------------------------------------- -------------------------- ------- ------ ------- ------- ------- ------- ----------------
  A/Perth/16/2009 (egg)†                    1,280                                  \<10                       \<10    \<10   20      20      \<10    \<10    2009 Apr 7
  A/Kansas/13/2009 (MDCK cells)             \<10                                   640                        80      160    40      40      40      80      2009 Jul 29
  A/Wisconsin/12/2010 (MDCK cells)          \<10                                   40                         1,280   320    640     320     640     1,280   2010 Sep 10
  A/Pennsylvania/14/2010 (egg)              \<10                                   160                        320     640    320     320     640     640     2010 Oct 26
  A/Minnesota/11/2010 (egg)                 \<10                                   \<10                       320     160    640     1,280   320     160     2010 Nov 26
  A/Minnesota/11/2010 X-203 (egg)‡          10                                     \<10                       80      40     320     640     160     80      Not applicable
  A/Indiana/08/2011 (MDCK cells)\*          \<10                                   10                         1,280   640    640     320     1,280   1,280   2011 Jul 24
  A/Indiana/10/2011 (MDCK cells)\*          \<10                                   40                         1,280   320    1,280   640     1,280   1,280   2011 Oct 22
  A/Indiana/10/2011 (egg)\*                 \<10                                   10                         1,280   320    640     320     1,280   1,280   2011 Oct 22
  A/Iowa/07/2011 (MDCK cells)\*             \<10                                   10                         1,280   640    1,280   640     1,280   2,560   2011 Nov 14
  A/Iowa/08/2011 (MDCK cells)\*             \<10                                   40                         1,280   640    640     640     1,280   2,560   2011 Nov 14
  A/Iowa/09/2011 (MDCK cells)\*             \<10                                   40                         1,280   640    1,280   640     2560    2,560   2011 Nov 14

\*Influenza A(H3N2)v, virus variant identified in humans, United States, 2011. Gray shading indicates antigenically similar viruses. †Current seasonal influenza A(H3N2) vaccine virus. ‡Reassortant virus possessing the hemagglutinin and neuraminidase genes of A/Minnesota/11/2010 and the remaining 6 genes of A/PR/8/34.

All influenza A(H3N2)v viruses tested were antigenically similar, demonstrating hemagglutination-inhibition titers with only a 2-fold difference from antiserum against other influenza A(H3N2)v viruses. These viruses were also antigenically closely related to earlier human triple-reassortant virus isolates that contained the M gene from classical SIVs (A/Wisconsin/12/2010, A/Pennsylvania/14/2010, and A/Minnesota/11/2010). All influenza A(H3N2)v viruses tested were also antigenically closely related to the proposed vaccine reassortant X-203 ([@R13]) between triple-reassortant A/Minnesota/11/2010 (H3N2) and A/PR/8/34 (H1N1) ([Table 2](#T2){ref-type="table"}).

The level of cross-protective immunity against influenza A(H3N2)v in humans previously vaccinated and/or exposed to previously circulated seasonal influenza A(H3N2) viruses is unknown. The antigenic characterization described here demonstrates that vaccination with the current trivalent influenza vaccine might not provide immune protection against influenza A(H3N2)v virus. A vaccine containing a contemporary influenza A(H3N2)v or an antigenically similar virus (such as A/Minnesota/11/2010) might be needed to elicit protective immunity.

Functional neuraminidase inhibition assays indicated that 6 influenza A(H3N2)v virus isolates were sensitive to the neuraminidase inhibitors oseltamivir and zanamivir. No genetic markers known to decrease sensitivity to neuraminidase inhibitors were found in the neuraminidase genes of all 12 influenza A(H3N2)v viruses. Similar to pandemic (H1N1) 2009 viruses, influenza A(H3N2)v viruses have genetic markers (V27A, S31N) in the M2 protein that confer resistance to the antiviral medications amantadine and rimantadine.

Conclusions
===========

The detection of multiple cases of human infection with influenza A(H3N2)v virus within a 5-month period in 5 US states, coupled with possible human-to-human transmission, underscores the need for continued influenza surveillance at the swine--human interface. Coordinated surveillance of human and animal influenza viruses enables rapid detection of human infections with novel influenza viruses and timely identification of new virus variants in swine. As was evident during the 2009 influenza pandemic, this information is vital for development of resources that might be needed to effectively respond to the emergence and spread of a novel influenza virus in humans.

Supplementary Material
======================

###### Technical Appendix

Phylogenetic analyses of protein genes and gene sequence accession numbers for influenza virus A(H3N2)v.
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